Peroxisome Proliferator-Activated Receptor-gamma in Amyotrophic Lateral Sclerosis and Huntington's Disease.
about
Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral SclerosisA comprehensive review of amyotrophic lateral sclerosisTelmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway.Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction.Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.Nuclear receptors in neurodegenerative diseases.Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration.Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse modelsInsulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets.Emerging drugs for amyotrophic lateral sclerosis.Brain activation of SIRT1: role in neuropathology.Natural Docosahexaenoic Acid in the Triglyceride Form Attenuates In Vitro Microglial Activation and Ameliorates Autoimmune Encephalomyelitis in Mice.Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.Potential role of sirtuin as a therapeutic target for neurodegenerative diseases.Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model.Protein-protein interactions reveal key canonical pathways, upstream regulators, interactome domains, and novel targets in ALS
P2860
Q26742196-D8E7C116-8AA0-49C8-A227-1F734DCD5963Q26775401-B2357B93-DA88-4875-BD3F-999E1A99368CQ33861931-72B7DE03-7322-4803-ACCE-6641F2DDD9B6Q34452078-01FED4B5-2331-49A5-9BC0-3944FAB1619CQ34508284-A3E2D1CB-874C-457D-90C0-B9EE8645FEF5Q34580020-F53AE654-46D9-40A0-803C-EE73388B3C06Q34933261-F10A8B8B-CC1F-43D7-AC1E-23D1F95C87AAQ36813115-C04E7CC3-F180-4759-9ECC-1026B8F72562Q37112122-8C128657-F56B-4CF3-8724-524D0F499B5DQ37689883-571B15C3-9B2A-43C0-895F-0D5E5CFC5AADQ37909351-30C6EBB2-74F0-4F25-9251-16D95CE525BDQ38101493-B8F74676-C8E3-4FD9-BF7B-700C6CC7FA4FQ38700383-B3EAFEAB-6C96-49E5-B43A-75BD5CC5DAE5Q41886732-A80D767D-0A73-4CEE-8DE2-C5DA05447869Q42234789-3D89305B-F8B8-4169-86FA-B2E7E5A77DCFQ42918972-79498742-CFCE-4755-81BF-0615FA09EF57Q57041934-4ED4C604-EA0E-4C15-AB5E-ECA4E8E6ADC4
P2860
Peroxisome Proliferator-Activated Receptor-gamma in Amyotrophic Lateral Sclerosis and Huntington's Disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Peroxisome Proliferator-Activa ...... osis and Huntington's Disease.
@en
Peroxisome Proliferator-Activa ...... osis and Huntington's Disease.
@nl
type
label
Peroxisome Proliferator-Activa ...... osis and Huntington's Disease.
@en
Peroxisome Proliferator-Activa ...... osis and Huntington's Disease.
@nl
prefLabel
Peroxisome Proliferator-Activa ...... osis and Huntington's Disease.
@en
Peroxisome Proliferator-Activa ...... osis and Huntington's Disease.
@nl
P2860
P356
P1433
P1476
Peroxisome Proliferator-Activa ...... osis and Huntington's Disease.
@en
P2093
Mahmoud Kiaei
P2860
P304
P356
10.1155/2008/418765
P577
2008-01-01T00:00:00Z